Agents in clinical development for the treatment of chronic hepatitis B.
Chronic hepatitis B remains a public health problem of global importance despite the availability of an effective vaccine. Between 350 and 400 million people, approximately 6% of the world's population, suffer from chronic hepatitis B and face a 30% likelihood of developing cirrhotic liver disease or hepatocellular carcinoma. Current treatment options include three monotherapies of subcutaneous interferon, oral nucleoside lamivudine and oral nucleotide adefovir dipivoxil. Unfortunately, these agents have not effectively and frequently been able to attain a 'cure' or complete eradication of the virus. Consequently, the expectation of current therapies is confined to the achievement of clinically beneficial and durable responses defined by lasting suppression of virus replication, histological improvement and increased survival for patients with decompensated liver diseases. Other disadvantages include the undesirable tolerability of interferon, the rapid resistance to lamivudine and the compromise between efficacy and toxicity that led to the development of the 10 mg dose of adefovir dipivoxil. Clearly, better therapeutics and treatment strategies are needed. Increased potency, activity against current treatment-refractory viruses, as well as efficacy in difficult-to-treat populations will be critical to meeting the therapeutic challenge of chronic hepatitis B.
Raney
Anneke K
AK
Ribapharm, Inc, Drug Discovery, 3300 Hyland Avenue, Costa Mesa, CA 92626, USA. araney@ribapharm.com
Hamatake
Robert K
RK
Hong
Zhi
Z
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000188:drug therapy* / Q000276:immunology; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents